Anthracycline Cardiotoxicity: From Bench to Bedside

SEER Cancer Statistics Review, 1975-2003

2006 • 11,387 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Cancer Statistics, 2006

2006 • 5,351 citations

Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

2004 • 3,483 citations

Chronic Health Conditions in Adult Survivors of Childhood Cancer

2006 • 3,305 citations

SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD

2011 • 2,409 citations

Risk Factors for Doxorubicin-lnduced Congestive Heart Failure

1979 • 2,308 citations

Congestive heart failure in patients treated with doxorubicin

2003 • 2,070 citations

Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages

2005 • 1,305 citations

USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2

2009 • 1,262 citations

Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis

2006 • 1,047 citations

Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy

2004 • 865 citations

Late Mortality Experience in Five-Year Survivors of Childhood and Adolescent Cancer: The Childhood Cancer Survivor Study

2001 • 776 citations

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

2007 • 765 citations

American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects

2007 • 760 citations

Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy

2006 • 686 citations

Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia

2005 • 675 citations

Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing Discipline

2004 • 661 citations

Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity

2005 • 616 citations

Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer

2007 • 611 citations

Tissue Doppler Imaging

2007 • 567 citations

Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

2007 • 558 citations

Topoisomerase IIβ–Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane

2007 • 550 citations

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience.

1997 • 466 citations

UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters

2007 • 459 citations

Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies

2005 • 451 citations

Early Breast Cancer Therapy and Cardiovascular Injury

2007 • 434 citations

Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility

2007 • 386 citations

Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury

1997 • 383 citations

Anthracycline associated cardiotoxicity in survivors of childhood cancer

2007 • 363 citations

Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast Cancer

1988 • 358 citations

Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity

2005 • 342 citations

ABVD Plus Subtotal Nodal Versus Involved-Field Radiotherapy in Early-Stage Hodgkin's Disease: Long-Term Results

2004 • 333 citations

Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study

2005 • 325 citations

Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults

2004 • 325 citations

Congestive Heart Failure After Treatment for Wilms’ Tumor: A Report From the National Wilms’ Tumor Study Group

2001 • 309 citations

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management

2007 • 305 citations

Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes

2004 • 300 citations

Long-Term Enalapril Therapy for Left Ventricular Dysfunction in Doxorubicin-Treated Survivors of Childhood Cancer

2002 • 291 citations

Enalapril to Prevent Cardiac Function Decline in Long-Term Survivors of Pediatric Cancer Exposed to Anthracyclines

2004 • 288 citations

Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect

1995 • 279 citations

Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity

2004 • 278 citations

Role of anthracyclines in the era of targeted therapy

2007 • 270 citations

2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology

2002 • 263 citations

Decreasing Late Mortality Among Five-Year Survivors of Cancer in Childhood and Adolescence: A Population-Based Study in the Nordic Countries

2001 • 259 citations

Neuregulin-1/erbB-Activation Improves Cardiac Function and Survival in Models of Ischemic, Dilated, and Viral Cardiomyopathy

2006 • 259 citations

Antioxidants and Cancer Therapy: A Systematic Review

2004 • 253 citations

N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?

2005 • 233 citations

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

1998 • 227 citations

Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions

2006 • 224 citations

Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic

1969 • 218 citations

Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis

2007 • 213 citations

Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study

2005 • 211 citations

Correlation Between Serum Levels of Cardiac Troponin-T and the Severity of the Chronic Cardiomyopathy Induced by Doxorubicin

1999 • 209 citations

Time-Dependent and Tissue-Specific Accumulation of mtDNA and Respiratory Chain Defects in Chronic Doxorubicin Cardiomyopathy

2003 • 209 citations

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

2006 • 207 citations

Chronic Health Conditions in Adult Survivors of Childhood Cancer

2007 • 203 citations

The "Final Common Pathway" Hypothesis and Inherited Cardiovascular Disease

2000 • 194 citations

Myocardial Dysfunction Late After Low-Dose Anthracycline Treatment in Asymptomatic Pediatric Patients

2007 • 191 citations

DNA damage is an early event in doxorubicin-induced cardiac myocyte death

2006 • 190 citations

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy

2006 • 189 citations

Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxorubicin and Breast Irradiation

2001 • 187 citations

Role of Neuregulin-1/ErbB2 Signaling in Endothelium-Cardiomyocyte Cross-talk

2006 • 175 citations

Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer

1996 • 175 citations

Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation–contraction coupling and reduces oxidative stress in adult rat cardiomyocytes

2006 • 167 citations

Molecular and cellular mechanisms of anthracycline cardiotoxicity

2007 • 156 citations

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert�panel�review

2004 • 155 citations

The Heart of the Matter

2008 • 150 citations

Chemical, Biological and Clinical Aspects of Dexrazoxane and Other Bisdioxopiperazines

1998 • 139 citations

Cancer and Cardiac Mortality Among 15-Year Survivors of Cancer Diagnosed During Childhood or Adolescence

1999 • 124 citations

Intracoronary Infusion of Skeletal Myoblasts Improves Cardiac Function in Doxorubicin-Induced Heart Failure

2001 • 124 citations

Noninvasive Evaluation of Late Anthracycline Cardiac Toxicity in Childhood Cancer Survivors

2007 • 123 citations

Role of mtDNA lesions in anthracycline cardiotoxicity

2007 • 120 citations

Monitoring for anthracycline cardiotoxicity.

1994 • 118 citations

Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

2007 • 112 citations

Monitoring for Anthracycline Cardiotoxicity

1994 • 108 citations

Pathophysiology and diagnosis of cancer drug induced cardiomyopathy

2007 • 102 citations

Anthracycline cardiotoxicity in long-term survivors of childhood cancer

2007 • 102 citations

Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.

1998 • 102 citations

Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats

1985 • 94 citations

Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer

2006 • 93 citations

Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart

2006 • 91 citations

The ATP-binding Cassette Transporter ABCG2 (BCRP), a Marker for Side Population Stem Cells, Is Expressed in Human Heart

2005 • 89 citations

Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897

2008 • 80 citations

Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies

2006 • 78 citations

Genotyping the risk of anthracycline-induced cardiotoxicity

2007 • 78 citations

Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors

2003 • 62 citations

In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity

2007 • 62 citations

Cardiac safety of liposomal anthracyclines

2007 • 60 citations

Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.

1981 • 59 citations

Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity

2007 • 46 citations

Monitoring of Anthracycline-Induced Cardiotoxicity

2007 • 46 citations

New iron chelators in anthracycline-induced cardiotoxicity

2007 • 40 citations

Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies

2006 • 38 citations

Myocardial Strain Analysis in a Doxorubicin-Induced Cardiomyopathy Model

2007 • 35 citations

Myocardial perfusion reserve and oxidative metabolism contribute to exercise capacity in patients with dilated cardiomyopathy

2004 • 31 citations

Exercise rehabilitation of pediatric patients with cardiovascular disease

2005 • 30 citations

Animal models of anthracycline cardiotoxicity: Basic mechanisms and cardioprotective activity

1997 • 29 citations

Antioxidant defense against anthracycline cardiotoxicity by metallothionein

2007 • 28 citations

Dystrophin‐deficiency increases the susceptibility to doxorubicin‐induced cardiotoxicity

2007 • 25 citations

A model system for measuring comparative toxicities of cardiotoxic drugs for cultured rat heart myocytes, endothelial cells and fibroblasts. II. Doxorubicin, 5-fluorouracil and cyclophosphamide

1984 • 24 citations

Iron signaling and oxidant damage

2007 • 22 citations

The relevance of information generated byin vitroexperimental models to clinical doxorubicin cardiotoxicity

2006 • 19 citations

Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy

1995 • 19 citations

Anthracycline-induced phospholipase A2 inhibition

2007 • 14 citations

Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen

2004 • 13 citations

Changes in Phospholipid Content and Myocardial Calcium-Independent Phospholipase A₂Activity during Chronic Anthracycline Administration

2004 • 12 citations

Endothelins: a Possible Mechanism of Cytostatics-induced Cardiomyopathy

2003 • 8 citations

Preliminary data of GOIM 2107 study: Multicenter phase II study of sequential hormonotherapy with anastrozole/exemestane in metastatic breast disease

2004 • 7 citations

Gemcitabine plus cisplatin in patients with locally advanced or metastatic breast cancer (MBC) who failed prior anthracycline therapy +/− taxanes

2004 • 3 citations